Literature DB >> 6975752

Cultured human T-cell lines kill autologous solid tumours.

B M Vose, M Moore.   

Abstract

Lymphocytes from peripheral blood, lymph node, spleen and tumour of 7 patients with various carcinomas (2 lung, 3 colon, 1 gastric and 1 parotid tumour) were cultured for 15 days in conditioned media containing T-cell growth factor (TCGF; Interleukin 2) after which their cytotoxic activity against autologous tumour (and in some instances, autologous normal) cells and allogeneic tumour targets was evaluated in a short-term 51Cr-release assay. Significant cytotoxicity against autologous tumour targets was detected in at least one effector preparation from all of the patients, under conditions where, in some cases, other autologous cells (normal lung, PHA-transformed lymphocytes) were resistant. This cytotoxicity also generally extended to allogeneic tumour targets, but lysis of K562, a cell line sensitive to natural killing, occurred in only 3 of 19 effector cell preparations. The data are consistent with a polyclonal expansion of cytotoxic T-cells of tumour-bearing patients which includes the amplification of a population recognitive of antigens expressed on autologous neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975752     DOI: 10.1016/0165-2478(81)90081-x

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

1.  Limiting dilution analysis (LDA) of cells responding to recombinant interleukin-2 without previous stimulation: evidence that all responding cells are lymphokine-activated potent effectors.

Authors:  H Vie; M Bonneville; P Sondermeyer; J F Moreau; J P Soulillou
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

Review 2.  Activation of lymphocyte anti-tumor responses in man. Towards an understanding of effector cell heterogeneity?

Authors:  B M Vose
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 3.  The foundations of immune checkpoint blockade and the ipilimumab approval decennial.

Authors:  Alan J Korman; Sarah C Garrett-Thomson; Nils Lonberg
Journal:  Nat Rev Drug Discov       Date:  2021-12-22       Impact factor: 112.288

4.  Human T-cell cultures with selective autotumor reactivity.

Authors:  F Vánky; E Klein
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  Tumour-reactive lymphocytes stimulated in mixed lymphocyte and tumour culture. Clonal analysis of effector cells in cytotoxic and proliferative assays.

Authors:  B M Vose; W White
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.

Authors:  Y Fujimiya; W C Chang; A Bakke; D Horwitz; P K Pattengale
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  The human mixed lymphocyte-tumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissues.

Authors:  E A Grimm; B M Vose; E W Chu; D J Wilson; M T Lotze; A A Rayner; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

8.  Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects.

Authors:  C Bindon; M Czerniecki; P Ruell; A Edwards; W H McCarthy; R Harris; P Hersey
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.